Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more)
Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Vanda Pharmaceuticals Inc
VNDA
Healthcare
Biotechnology
Vanda Pharmaceuticals Inc. (Vanda) is a global biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Vanda's commercial portfolio is comprised of two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum...
disorder (ASD) and pediatric Non-24 and Fanapt for the treatment of bipolar I disorder and Parkinsons disease psychosis and a long acting injectable (LAI) formulation for the treatment of schizophrenia. In addition, the Company has a range of drugs in development, including Tradipitant (VLY-686), for the treatment of gastroparesis, motion sickness, atopic dermatitis, and Covid-19 pneumonia; VTR-297 for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications, and VQW-765, for the treatment of performance anxiety and psychiatric disorders.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:VNDA)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
JGrabar
X
Post by
JGrabar
on May 31, 2022 9:59am
$VNDA -Settlement
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
AI Alchemy: Turning Data into Gold with Artificial Intelligence
Positive PEA Announced for Proposed Lithium Mining Operation in Ontario
Assays of 14.8% Cu over 2.45 Metres at Historic Canadian Copper Mine drives Record Volume
814 gpt Silver Over 1.0 M Within 6 Meters of 435 gpt and 174 gpt Over 22 M at Columba Silver Project
Emperor Metals Intersects Near Surface Mineralization; Building Bulk Tonnage Open Pit Potential at Duquesne West Gold Project in Quebec
New Images for the Passive Seismic Survey Very Promising for the Topaz Helium Project in Minnesota
Learn How a Pharma R&D Company Can De-Risk Your Healthcare Portfolio
POET Technologies Issues Letter to Shareholders
Silver is Considered a Safe Haven Asset But the White Metal Has Far More to it Than Meets the Eye
NexOptic Begins Announcing New Team Additions